Malignant fibrous histiocytoma following radiation therapy and chemotherapy for Hodgkin's lymphoma

Int J Clin Oncol. 2007 Feb;12(1):52-5. doi: 10.1007/s10147-006-0624-z. Epub 2007 Feb 25.

Abstract

Malignant fibrous histiocytoma (MFH) originates from primitive mesenchymal cells and has the capacity for dual differentiation into histiocytes and fibroblasts. MFH occurring as a secondary malignancy following radio-chemotherapy is rare and its exact incidence is not yet known. Here we report a case of a 42-year-old man who developed MFH in his right knee over a period of more than 10 years after radio (44 Gy)-chemotherapy to treat Hodgkin's lymphoma. After the diagnosis the patient did not return and was lost to follow-up. This is a rare case with unusual presentation, and it highlights the importance of the awareness and prevention of such secondary tumors.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bleomycin / adverse effects
  • Bone Neoplasms / etiology*
  • Chemotherapy, Adjuvant
  • Dacarbazine / adverse effects
  • Doxorubicin / adverse effects
  • Histiocytoma, Malignant Fibrous / etiology*
  • Hodgkin Disease / drug therapy
  • Hodgkin Disease / pathology
  • Hodgkin Disease / radiotherapy
  • Hodgkin Disease / therapy*
  • Humans
  • Male
  • Mechlorethamine / adverse effects
  • Muscle Neoplasms / etiology*
  • Neoplasms, Radiation-Induced / etiology
  • Prednisone / adverse effects
  • Procarbazine / adverse effects
  • Radiotherapy, Adjuvant
  • Vinblastine / adverse effects
  • Vincristine / adverse effects

Substances

  • Bleomycin
  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Vinblastine
  • Dacarbazine
  • Doxorubicin
  • Prednisone

Supplementary concepts

  • ABVD protocol
  • MOPP protocol